intedanib therapy will improve management in covid 19 fibrosis if given early or not.
Not Applicable
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/12/029783
- Lead Sponsor
- PRATIMA SINGH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All cases of covid 19 pneumonia detected as COVID positive within <= 30 days or with history and CT suggestive of covid 19 .
CT-severity score >=15 and CORADS-4/5/6
Exclusion Criteria
-Patients having other interstitial lung diseases.
- Patient having CKD or creatinine clearance <30 and CLD with deranged LFT will be excluded.
-Not fulfilling the criteria for study
-Not giving consent for study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in CT thorax findings(CT severity score).Timepoint: 6WEEKS 12WEEKS.
- Secondary Outcome Measures
Name Time Method improvement in CT-severity scoreTimepoint: 6 WEEKS, 12 WEEKS